Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
Journal of Medical Economics
|
May 7, 2025
Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study
Brian J Ball, Rui Song, Enrico Zanardo, et al.
Transfusion
|
September 10, 2021
Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: A real-world analysis
Chao-Hsiun Tang, Wesley Furnback, Bruce C M Wang, et al.
Journal of Medical Economics
|
September 2, 2025
Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review
Lucio N Gordan, Gustavo Fonseca, Amanda Warner, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 26, 2018
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
Rohit Mistry, Jessica R May, Gaurav Suri, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 23, 2007
RNA interference screen to identify genes required for Drosophila embryonic nervous system development
Keita Koizumi, Haruhiro Higashida, Siuk Yoo, et al.
Leukemia Research
|
November 27, 2024
Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study
Leslie A Andritsos, Ali McBride, Derek Tang, et al.
Current Medical Research and Opinion
|
July 24, 2018
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer
Rohit Mistry, Gaurav Suri, Kate Young, et al.
Leukemia & Lymphoma
|
June 23, 2025
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY
Michael J Mauro, Rüdiger Hehlmann, Loretta A Williams, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
March 29, 2022
Health state utilities for beta-thalassemia: a time trade-off study
Antony P Martin, Enrico Ferri Grazzi, Claudia Mighiu, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 15, 2023
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
John Mascarenhas, Claire Harrison, Tammy A Schuler, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
Journal of Medical Economics
|
May 7, 2025
Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study
Brian J Ball, Rui Song, Enrico Zanardo, et al.
Transfusion
|
September 10, 2021
Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: A real-world analysis
Chao-Hsiun Tang, Wesley Furnback, Bruce C M Wang, et al.
Journal of Medical Economics
|
September 2, 2025
Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review
Lucio N Gordan, Gustavo Fonseca, Amanda Warner, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 26, 2018
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
Rohit Mistry, Jessica R May, Gaurav Suri, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 23, 2007
RNA interference screen to identify genes required for Drosophila embryonic nervous system development
Keita Koizumi, Haruhiro Higashida, Siuk Yoo, et al.
Leukemia Research
|
November 27, 2024
Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study
Leslie A Andritsos, Ali McBride, Derek Tang, et al.
Current Medical Research and Opinion
|
July 24, 2018
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer
Rohit Mistry, Gaurav Suri, Kate Young, et al.
Leukemia & Lymphoma
|
June 23, 2025
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY
Michael J Mauro, Rüdiger Hehlmann, Loretta A Williams, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
March 29, 2022
Health state utilities for beta-thalassemia: a time trade-off study
Antony P Martin, Enrico Ferri Grazzi, Claudia Mighiu, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 15, 2023
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
John Mascarenhas, Claire Harrison, Tammy A Schuler, et al.
Page
of 4